Karl Herholz

Overview

Best Publications

• Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography : Review and 1999 EORTC recommendations

  H. Young;R. Baum;U. Cremerius;K. Herholz

  2014
  Citations

• Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET

  Karl Herholz;Eric Salmon;Daniela Perani;Jean-Claude Baron

  1018
  Citations

• Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias

  Lisa Mosconi;Wai H. Tsui;Wai H. Tsui;Karl Herholz;Alberto Pupi

  873
  Citations

• Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

  Harald Hampel;Richard Frank;Karl Broich;Stefan J. Teipel

  803
  Citations

• The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders.

  Volker Sturm;Doris Lenartz;Athanasios Koulousakis;Harald Treuer

  689
  Citations

• Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

  Giovanni B Frisoni;Marina Boccardi;Frederik Barkhof;Kaj Blennow;Kaj Blennow

  651
  Citations

• Progressive derangement of periinfarct viable tissue in ischemic stroke.

  W.-D. Heiss;M. Huber;G. R. Fink;K. Herholz

  574
  Citations

• Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

  Gaël Chételat;Javier Arbizu;Henryk Barthel;Valentina Garibotto

  498
  Citations

• 11C-methionine PET for differential diagnosis of low-grade gliomas

  K. Herholz;T. Hölzer;B. Bauer;R. Schröder

  491
  Citations

• Dementia in Parkinson disease Functional imaging of cholinergic and dopaminergic pathways

  Rüdiger Hilker;A. V. Thomas;J. C. Klein;S. Weisenbach

  434
  Citations

• MCI conversion to dementia and the APOE genotype A prediction study with FDG-PET

  L. Mosconi;D. Perani;S. Sorbi;Karl Herholz

  434
  Citations

• An Interactive Technique for Three-Dimensional Image Registration: Validation for PET, SPECT, MRI and CT Brain Studies

  Uwe Pietrzyk;Karl Herholz;Gereon Fink;Andreas Jacobs

  413
  Citations

• Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to alzheimer disease

  Davide Anchisi;Barbara Borroni;Massimo Franceschi;Nasser Kerrouche

  378
  Citations

• Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

  Ruediger Hilker;Katherine Schweitzer;Silke Coburger;Mehran Ghaemi

  360
  Citations

• Brain plasticity in poststroke aphasia: what is the contribution of the right hemisphere?

  Hans Karbe;Alexander Thiel;Gerald Weber-Luxenburger;Karl Herholz

  356
  Citations

• Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

  Lutz W. Kracht;Hrvoje Miletic;Susanne Busch;Andreas H. Jacobs

  351
  Citations

• Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature

  Nicolaas I. Bohnen;David S.W. Djang;Karl Herholz;Yoshimi Anzai

  350
  Citations

• Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET.

  P R Luyten;A J Marien;W Heindel;P H van Gerwen

  348
  Citations

• Astrocyte Biomarkers in Alzheimer's Disease.

  Stephen F. Carter;Karl Herholz;Pedro Rosa-Neto;Pedro Rosa-Neto;Luc Pellerin;Luc Pellerin

  320
  Citations

• 18F-Fluoro-l-Thymidine and 11C-Methylmethionine as Markers of Increased Transport and Proliferation in Brain Tumors

  Andreas H. Jacobs;Anne Thomas;Lutz W. Kracht;Huongfeng Li

  310
  Citations

• PET studies in dementia.

  Karl Herholz

  303
  Citations